{
    "nct_id": "NCT04628494",
    "official_title": "A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",
    "inclusion_criteria": "1. Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since lymphoma diagnosis\n2. One of the confirmed histologies below with CD20-positivity:\n\n   1. DLBCL, NOS, including de novo or histologically transformed from FL\n   2. \"Double-hit\" or \"triple-hit\" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations), including de novo or histologically transformed from FL\n   3. FL Grade 3B\n   4. T-cell/histiocyte-rich large B-cell lymphoma\n3. ECOG PS score of 0-2\n4. Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening\n5. Patients must have detectable disease by PET scan and measurable by CT scan or MRI\n6. Acceptable renal and liver function\n7. Life expectancy >2 months on SOC treatment\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Primary Central Nervous System (CNS) tumor or known CNS involvement\n2. Any prior therapy with a bispecific antibody targeting CD3 and CD20\n3. Major surgery within 4 weeks prior to randomization\n4. Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization\n5. Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization\n6. ASCT within 100 days of randomization\n7. Treatment with CAR-T therapy within 100 days prior to randomization\n8. Seizure disorder requiring anti-epileptic therapy\n9. Clinically significant cardiac disease",
    "miscellaneous_criteria": "Main"
}